BioFocus, a leading provider of gene-to-drug candidate discovery services, today announced that Dr. John Nash has joined BioFocus as Senior Director, ADME/PK. John has 30 years industrial experience with both service and major pharmaceutical companies.  Most recently, John worked for eight years for Charles River Laboratories in Quebec, Canada, where he was responsible for strengthening the DMPK service business, and making it a successful, revenue generating operation. Prior to moving to Canada, John worked in the UK with Anserve and AstraZeneca/Syngenta in metabolism and pharmacokinetics. John holds an M. Phil. degree from the University of Surrey and a Ph. D. degree from the University of Manchester.

“John Nash’s appointment is a major win for BioFocus in the UK,” commented Dr. Chris Newton, SVP BioFocus. “With this hire, BioFocus continues to elevate its 175 scientist facility at Chesterford Research Park into a leading integrated discovery research center for pharma, biotech and not-for-profit organizations worldwide.”

About BioFocus

BioFocus aims to expand its partners’ drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As the service division of Galapagos, BioFocus has over 250 employees in four countries worldwide.